{ "id": "epr2ztz00a", "slug": "hla-typing", "title": "HLA typing", "updated": "2026-09-30", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical" }, { "id": "life.health.clinical.clinical-transplantation", "label": "Organ and tissue transplantation", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-transplantation" }, { "id": "life.health.clinical.clinical-transplantation.alpha-a-to-la", "label": "Titles A to La", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-transplantation.alpha-a-to-la" } ], "geo": [ { "id": "geo.nongeo.t1946.life.health.clinical.clinical-transplantation", "label": "Non-geographic · 1946 to 2000: Organ and tissue transplantation", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-transplantation", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t1946", "label": "Non-geographic · 1946 to 2000", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946" }, { "id": "geo.nongeo.t1946.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life" }, { "id": "geo.nongeo.t1946.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health" }, { "id": "geo.nongeo.t1946.life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical" }, { "id": "geo.nongeo.t1946.life.health.clinical.clinical-transplantation", "label": "Organ and tissue transplantation", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-transplantation" } ] } ], "excerpt": "HLA typing is the laboratory and computational determination of which human leukocyte antigen alleles a person carries, underpinning transplant donor matching, disease association studies, and drug safety screening.", "snippet": "HLA typing is the laboratory and computational determination of which human leukocyte antigen alleles a person carries, underpinning transplant donor matching, disease association studies, and drug safety screening.", "node": "life.health.clinical.clinical-transplantation.alpha-a-to-la", "markdown": "# HLA typing\n\nHLA typing is the laboratory and computational determination of which human leukocyte antigen (HLA) alleles a person carries at the classical loci HLA-A, -B, -C, -DR, -DQ, and -DP. It underpins donor-recipient matching in transplantation, disease association studies, and pharmacogenetic screening before drugs such as abacavir and carbamazepine.[1](https://www.sciencedirect.com/science/article/pii/S0198885911001467) • [2](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.652258/full) • [3](https://www.sciencedirect.com/science/article/abs/pii/S0198885919314363) A typing result reports a pair of alleles per locus at a stated resolution: low resolution assigns first-field digits (A\\*01; A\\*02), intermediate resolution gives G-group designations such as A\\*02:01:01G, and high resolution assigns two-field alleles encoding the same antigen-binding-site protein sequence.[1](https://www.sciencedirect.com/science/article/pii/S0198885911001467) The achievable resolution depends on the assay and on which alleles must be distinguished: non-sequencing methods are not inherently limited to intermediate resolution, and sequencing methods can also leave ambiguities.[1](https://www.sciencedirect.com/science/article/pii/S0198885911001467)\n\n| Key fact | Value |\n|---|---|\n| Loci typed | HLA-A, -B, -C, -DRB1/3/4/5, -DQA1, -DQB1, -DPA1, -DPB1 (11 genes in modern panels)[4](https://omixon-download.s3.amazonaws.com/Omixon_HLA_User_Manuals/NanoTYPE%20CE/v2/NanoTYPE_IFU_CE_Rev2.pdf) |\n| Allele diversity | More than 40,000 HLA alleles described in IPD-IMGT/HLA; the latest release, version 3.65 (2026-07), lists 46,652 distinct allelic variants with 82,661 component entries[5](https://www.analytik-jena.com/import/assets/12760398_AppNote_PCR_0001_HLA_Sequencing_Library_Preparation_TAdvanced_SG_en.pdf) • [6](https://www.biorxiv.org/content/10.1101/2025.10.23.684216v1.full.pdf) |\n| Gold-standard eras | Serology (CDC) for over 25 years; Sanger SBT 1996-2016; NGS thereafter[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC11732764/) • [8](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1551173/full) |\n| NGS amplicon accuracy | 99.9% at allele level (AllType, Ion S5); 99.91% four-field (96-sample nanopore workflow)[9](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0232050) • [10](https://pmc.ncbi.nlm.nih.gov/articles/PMC12019580/) |\n| Turnaround | Under 3 h (SSP Phototyping); 5.5-10.5 h DNA-to-result (nanopore); 3-5 days (Illumina whole-gene)[11](https://onlinelibrary.wiley.com/doi/10.1111/j.1399-0039.1995.tb03127.x) • [10](https://pmc.ncbi.nlm.nih.gov/articles/PMC12019580/) • [12](https://omixon-download.s3.amazonaws.com/Omixon_HLA_User_Manuals/Holotype+RUO+2.2.1/Holotype+HLA+24_11+RUO+User+Manual+Protocol+version+2.2.1+-+IFU+v2.pdf) |\n| Transplant matching | 8/8 match at HLA-A, -B, -C, -DRB1 is the preferred US donor-selection target, not an absolute requirement; 10/10 adds -DQB1 (most European centers)[2](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.652258/full) |\n| Pharmacogenomic mandates | FDA labeling for abacavir and carbamazepine includes HLA-B screening recommendations (ancestry-specific for carbamazepine), not a universal requirement; CPIC guidance addresses using results, such as avoiding allopurinol in HLA-B*58:01-positive patients[3](https://www.sciencedirect.com/science/article/abs/pii/S0198885919314363) |\n\n## How it works\n\n[Sequence-based typing](https://www.edgepedia.org/sequence-based-typing) (SBT) and next-generation sequencing (NGS) read the nucleotide sequence directly and match it against the IPD-IMGT/HLA reference database.[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC11732764/) • [11](https://onlinelibrary.wiley.com/doi/10.1111/j.1399-0039.1995.tb03127.x)\n\nBecause the database keeps growing, the reference version is part of the result: the American Society for Histocompatibility and Immunogenetics requires typing databases to be updated with the most recent IPD-IMGT/HLA version at least every 12 months.[2](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.652258/full)\n\n## How it is done\n\nA modern sequence-based workflow runs as follows, illustrated by the Omixon Holotype HLA protocol for Illumina MiSeq:[12](https://omixon-download.s3.amazonaws.com/Omixon_HLA_User_Manuals/Holotype+RUO+2.2.1/Holotype+HLA+24_11+RUO+User+Manual+Protocol+version+2.2.1+-+IFU+v2.pdf)\n\n1. Extract genomic DNA; the Holotype protocol requires 1.0-1.5 µg per sample.\n2. Amplify HLA genes by long-range PCR: HLA-A, -B, -C, -DPA1, -DQA1, and -DQB1 over their entire coding length, DRB1/DRB3 from intron 1 to intron 4, DRB5 and DPB1 from intron 1 to the 3' UTR.[5](https://www.analytik-jena.com/import/assets/12760398_AppNote_PCR_0001_HLA_Sequencing_Library_Preparation_TAdvanced_SG_en.pdf)\n3. Quantitate and normalize amplicons, pool them, prepare sequencing libraries (fragmentation, end repair, adaptor ligation), and size-select with AMPure XP beads.\n4. Sequence on MiSeq (3-5 days total) or, for nanopore workflows, on MinION/GridION after a single long-range multiplex PCR of 11 loci from 200 ng of gDNA with template longer than 6.5 kb.[12](https://omixon-download.s3.amazonaws.com/Omixon_HLA_User_Manuals/Holotype+RUO+2.2.1/Holotype+HLA+24_11+RUO+User+Manual+Protocol+version+2.2.1+-+IFU+v2.pdf) • [4](https://omixon-download.s3.amazonaws.com/Omixon_HLA_User_Manuals/NanoTYPE%20CE/v2/NanoTYPE_IFU_CE_Rev2.pdf)\n5. Call alleles with software against IPD-IMGT/HLA, for example HLATwin with two independent algorithms, NanoTYPER, or NGSEngine.\n\nFor high throughput, a microfluidic workflow amplifies exons 2 and 3 of six loci on Fluidigm Access Array chips and sequences 384 samples in one MiSeq run, with routine capacity of 12,000 samples per week.[13](https://link.springer.com/article/10.1186/1471-2164-15-63) Read depth matters for resolution: 50X supports more than 90% second-field accuracy, while 100X is needed for 90% third-field accuracy with HLA-HD and HISAT-genotype, the two most accurate of seven benchmarked NGS algorithms, followed by HLAscan.[2](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.652258/full)\n\n## Origin\n\nHLA was described through leukocyte agglutination reactions in sera of repeatedly transfused patients, naming the antigen MAC (later HLA-A2). The complement-dependent cytotoxicity microassay remained the primary typing method for over 25 years, and HLA-DR specificities were reported serologically in 1977 at the 7th International Histocompatibility Testing workshop.[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC11732764/) DNA-based typing arrived with PCR: Olerup and Zetterquist reported HLA-DR typing by PCR-SSP in 2 hours in 1992,[14](https://doi.org/10.1111/j.1399-0039.1992.tb01940.x) and Bunce and colleagues introduced Phototyping, comprehensive typing of eight loci with 144 primer mixes, in 1995.[11](https://onlinelibrary.wiley.com/doi/10.1111/j.1399-0039.1995.tb03127.x) SSOP approaches for [HLA-B](https://www.edgepedia.org/hla-b) fine specificity and for class I high- and intermediate-resolution typing followed in 1995 and 1999.[15](https://doi.org/10.1111/j.1399-0039.1995.tb02494.x) SBT for class I was reported by Santamaria and colleagues in 1993,[16](https://doi.org/10.1016/0198-8859%2893%2990141-m) building on Sanger chain-termination sequencing of 1977[17](https://doi.org/10.1073/pnas.74.12.5463) and on Cereb and colleagues' 1995 intron-based locus-specific amplification of HLA-A, -B, and -C.[18](https://doi.org/10.1111/j.1399-0039.1995.tb02408.x) SBT was considered the gold standard from 1996 until 2016, when NGS took over.[8](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1551173/full) HLA genotyping by next-generation sequencing using 454 pyrosequencing was reported by Bentley and colleagues in 2009,[19](https://doi.org/10.1111/j.1399-0039.2009.01345.x) with dedicated software such as SBTengine (2005) supporting the SBT era.[20](https://doi.org/10.1016/j.humimm.2005.08.061)\n\n## Variants\n\n**SSP (Phototyping).** 144 sequence-specific primer reactions detect all known HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, and DQB1 specificities under identical PCR conditions, with results in under 3 hours and resolution greater than or equivalent to good serology.[11](https://onlinelibrary.wiley.com/doi/10.1111/j.1399-0039.1995.tb03127.x)\n\n**SSOP.** Generic locus amplification followed by probe hybridization supports high- and intermediate-resolution typing, but leaves ambiguities that limit clinical disease-association testing.[3](https://www.sciencedirect.com/science/article/abs/pii/S0198885919314363)\n\n**SBT.** Sanger sequencing of PCR-amplified exons, historically paired with software such as SBTengine.[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC11732764/) • [20](https://doi.org/10.1016/j.humimm.2005.08.061)\n\n**Short-read amplicon NGS.** Two designs dominate: exon-focused multiplex panels (Fluidigm/MiSeq, 384 samples per run)[13](https://link.springer.com/article/10.1186/1471-2164-15-63) and whole-gene multiplex long-range PCR such as AllType, which amplifies 11 transplant-relevant genes in one reaction for Ion S5 sequencing with 98.6%, 99.8%, and 99.9% concordance at sample, genotype, and allele levels.[9](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0232050)\n\n**Long-read NGS.** PacBio SMRT and Oxford Nanopore sequence entire HLA genes without assembling short reads, removing phasing ambiguity (inability to tell which variants sit on the same chromosome); PacBio raw error of 13-15% falls to 99.999% consensus accuracy with circular consensus sequencing, while ONT raw error is 10-15% on MinION.[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC11732764/) Products include Omixon Holotype (Illumina whole-gene) and NanoTYPE (nanopore, 11 loci).[12](https://omixon-download.s3.amazonaws.com/Omixon_HLA_User_Manuals/Holotype+RUO+2.2.1/Holotype+HLA+24_11+RUO+User+Manual+Protocol+version+2.2.1+-+IFU+v2.pdf) • [4](https://omixon-download.s3.amazonaws.com/Omixon_HLA_User_Manuals/NanoTYPE%20CE/v2/NanoTYPE_IFU_CE_Rev2.pdf)\n\n**Capture, WGS, and RNA-based typing.** [Hybrid capture](https://www.edgepedia.org/hybrid-capture) enriches classical and non-classical HLA genes plus all 69 protein-coding MHC class III genes without long-range PCR.[21](https://www.medrxiv.org/content/10.64898/2026.03.27.26349549v4) Whole-genome and RNA-seq data can be typed directly: consHLA combines germline WGS (~30X), tumor WGS (~90X), and tumor RNA-seq into a consensus reaching 97.9% concordance with clinical typing across 12 genes at three-field resolution, and SpecHLA enables full-resolution typing from short-read sequencing data.[22](https://doi.org/10.1186/s12859-025-06223-z) • [23](https://doi.org/10.1016/j.crmeth.2023.100589)\n\n## Applications\n\n**Hematopoietic stem cell transplantation.** US guidelines prefer an 8/8 allele match at HLA-A, -B, -C, and -DRB1 when such donors are likely to be available, and a single mismatch at these loci is associated with a 25% increase in post-transplant complications; most European centers seek 10/10 matching by adding [HLA-DQB1](https://www.edgepedia.org/hla-dqb1).[2](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.652258/full) • [26](https://network.nmdp.org/-/media/project/nmdp/networkresourcecenter/pdfs/services-support/materials-catalog/np24365_donor-selection-guidelines_2025-07-23_digital.pdf?rev=ca5eca0935de408aa028800fbb65e299) After ultra-high-resolution four-field typing with PacBio SMRT sequencing, HLA match status changed in 29% of pairs, a direct consequence of resolving alleles that two-field typing collapses.[2](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.652258/full)\n\n**Solid organ transplantation.** High-resolution two-field typing was highly instructive or necessary in 41% (156/385) of retrospectively evaluated NGS-typed cases at one center, and 21% at another.[1](https://www.sciencedirect.com/science/article/pii/S0198885911001467)\n\n**Pharmacogenomics.** FDA labeling recommends HLA-B screening before abacavir therapy and ancestry-specific screening before carbamazepine therapy, while CPIC and the [American College of Rheumatology](https://www.edgepedia.org/american-college-of-rheumatology) recommend testing before allopurinol, targeting B\\*57:01, B\\*15:02, and B\\*58:01 respectively.[3](https://www.sciencedirect.com/science/article/abs/pii/S0198885919314363) [Abacavir](https://www.edgepedia.org/abacavir) induces an immune-mediated hypersensitivity response correlating with B\\*57:01 in 5-8% of treated patients, and guidelines recommend screening before initiation.[24](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0123525)\n\n**Disease association.** Subtype resolution changes conclusions: B\\*27:06 and B\\*27:09 are not associated with ankylosing spondylitis, while B\\*27:04 and B\\*27:05 play a distinct role in pathogenesis, so broad B\\*27-family typing without two-field subtype resolution is insufficient to distinguish these subtypes.[3](https://www.sciencedirect.com/science/article/abs/pii/S0198885919314363) In head-to-head testing for celiac, narcolepsy, and drug-hypersensitivity alleles, NGS was the most accurate method compared with SSOP and real-time PCR melting-curve assays.[3](https://www.sciencedirect.com/science/article/abs/pii/S0198885919314363)\n\n## Limitations and alternatives\n\nAccuracy has improved stepwise with each chemistry. One study reported a 25% error rate in serological HLA-B typing, and even current PCR-based gold-standard methods show only 84% concordance across laboratories.[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC11732764/) • [2](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.652258/full) SBT left 41% of HLA-A and 24% of HLA-B results ambiguous; NGS integrating two software programs reached 100% genotyping accuracy with 0.8% ambiguity in one study.[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC11732764/)\n\nResidual NGS ambiguity has identifiable causes. Illumina and [Ion Torrent](https://www.edgepedia.org/ion-torrent) reads of 100-300 bp cannot span full HLA genes, leaving phasing ambiguity; in the AllType assay, 80.6% of ambiguous genotypes (116 of 144) stemmed from missing exon 1 and intron 1 coverage of HLA-DRB1/DRB345/DQB1/DPB1.[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC11732764/) • [9](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0232050) Allele amplification bias is a further failure mode: imbalanced amplification of up to 20:1 between alleles occurs in microfluidic amplicon typing,[13](https://link.springer.com/article/10.1186/1471-2164-15-63) and a 96-sample nanopore study produced one false homozygous call because DQB1\\*03:02:01G failed to amplify.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC12019580/) Software misassignment also occurs: among 15 ambiguous results compared across three methods, discrepancies were attributed to software misassignment rather than true sequence differences.[8](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1551173/full) For nanopore data, denoising pipelines matter: a BWA-MEM voting pipeline outperformed HLA-LA at third-field concordance (93.1% vs 86.4% in development; 90.1% vs 81.0% in test), and read-count ratios distinguish heterozygous from homozygous calls for non-HLA-DRB genes but not for HLA-DRB genes.[25](https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-025-11547-4)\n\nThe 96-sample nanopore workflow costs about €7 per sample with DNA-to-result in 5.5-10.5 h, and ONT covers larger HLA regions with roughly 3 h sequencing turnaround versus up to 2 days for short reads.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC12019580/) • [25](https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-025-11547-4) Long-read alternatives trade error rate for phasing: FuFiHLA on PacBio HiFi reads reached 99.57% full four-field accuracy on 47 HPRC samples, but on Nanopore R10 reads fourth-field accuracy fell to 87.0%, mainly from intronic homopolymer errors.[6](https://www.biorxiv.org/content/10.1101/2025.10.23.684216v1.full.pdf) HLA-Resolve, pairing hybrid capture with PacBio HiFi, reached 99.5% three-field and 90.5% four-field concordance.[21](https://www.medrxiv.org/content/10.64898/2026.03.27.26349549v4)\n\n## References\n\n1. [Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group (Human Immunology)](https://www.sciencedirect.com/science/article/pii/S0198885911001467)\n2. [Benchmarking the Human Leukocyte Antigen Typing Performance of Three Assays and Seven NGS-Based Algorithms](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.652258/full)\n3. [Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing (Human Immunology)](https://www.sciencedirect.com/science/article/abs/pii/S0198885919314363)\n4. [Omixon NanoTYPE CE Instructions for Use (Oxford Nanopore HLA genotyping)](https://omixon-download.s3.amazonaws.com/Omixon_HLA_User_Manuals/NanoTYPE%20CE/v2/NanoTYPE_IFU_CE_Rev2.pdf)\n5. [HLA Typing Using Long-Range PCR and Next-Generation Sequencing (Analytik Jena application note)](https://www.analytik-jena.com/import/assets/12760398_AppNote_PCR_0001_HLA_Sequencing_Library_Preparation_TAdvanced_SG_en.pdf)\n6. [FuFiHLA: A tool for Full-Field HLA typing from long reads data (bioRxiv preprint, 2025)](https://www.biorxiv.org/content/10.1101/2025.10.23.684216v1.full.pdf)\n7. [A walk through the development of human leukocyte antigen typing: from serologic techniques to next-generation sequencing](https://pmc.ncbi.nlm.nih.gov/articles/PMC11732764/)\n8. [Optimized multiplex PCR-NGS for comprehensive HLA genotyping in Chinese populations: resolving ambiguities at high resolution (Frontiers in Immunology, 2025)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1551173/full)\n9. [Performance of a multiplexed amplicon-based next-generation sequencing assay for HLA typing (AllType, PLOS One)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0232050)\n10. [Cost-Effective and Highly Scalable Typing of HLA Classes I and II Genes of up to 96 Individuals Using Nanopore Sequencing (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12019580/)\n11. [Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (Bunce et al., Tissue Antigens, 1995)](https://onlinelibrary.wiley.com/doi/10.1111/j.1399-0039.1995.tb03127.x)\n12. [Omixon Holotype HLA RUO User Manual Protocol v2.2.1](https://omixon-download.s3.amazonaws.com/Omixon_HLA_User_Manuals/Holotype+RUO+2.2.1/Holotype+HLA+24_11+RUO+User+Manual+Protocol+version+2.2.1+-+IFU+v2.pdf)\n13. [Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing (BMC Genomics)](https://link.springer.com/article/10.1186/1471-2164-15-63)\n14. [Ole Olerup, Henrik Zetterquist (1992). HLA‐DR typing by PCR amplification with sequence‐specific primers (PCR‐SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor‐recipient matching in cadaveric transplantation. Tissue Antigens.](https://doi.org/10.1111/j.1399-0039.1992.tb01940.x)\n15. [K. Fleischhauer and colleagues (1995). Complete generic and extensive fine‐specificity typing of the HLA‐B locus by the PCR‐SSOP method. Tissue Antigens.](https://doi.org/10.1111/j.1399-0039.1995.tb02494.x)\n16. [HLA class I sequence-based typing (Human Immunology, 1993)](https://doi.org/10.1016/0198-8859%2893%2990141-m)\n17. [F. Sanger, S. Nicklen, A. R. Coulson (1977). DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences.](https://doi.org/10.1073/pnas.74.12.5463)\n18. [N. Cereb and colleagues (1995). Locus‐specific amplification of HLA class I genes from genomic DNA: locus‐specific sequences in the first and third introns of HLA‐A, ‐B, and ‐C alleles. Tissue Antigens.](https://doi.org/10.1111/j.1399-0039.1995.tb02408.x)\n19. [G. Bentley and colleagues (2009). High‐resolution, high‐throughput HLA genotyping by next‐generation sequencing. Tissue Antigens.](https://doi.org/10.1111/j.1399-0039.2009.01345.x)\n20. [Erik H. Rozemuller and colleagues (2005). SBTengine®, a sophisticated and versatile HLA sequencing based typing software. Human Immunology.](https://doi.org/10.1016/j.humimm.2005.08.061)\n21. [HLA-Resolve: Four-field HLA typing and MHC variant detection from long-read hybrid capture (medRxiv preprint, 2026)](https://www.medrxiv.org/content/10.64898/2026.03.27.26349549v4)\n22. [Rachel Bowen-James and colleagues (2025). consHLA: a next generation sequencing consensus-based HLA typing workflow. BMC Bioinformatics.](https://doi.org/10.1186/s12859-025-06223-z)\n23. [Shuai Wang and colleagues (2023). SpecHLA enables full-resolution HLA typing from sequencing data. Cell Reports Methods.](https://doi.org/10.1016/j.crmeth.2023.100589)\n24. [Comparison of Methods for In-House Screening of HLA-B*57:01 to Prevent Abacavir Hypersensitivity in HIV-1 Care (PLOS One)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0123525)\n25. [A computational HLA allele-typing protocol to de-noise and leverage nanopore amplicon data (BMC Genomics, 2025)](https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-025-11547-4)\n26. [Np24365 Donor Selection Guidelines 2025 07 23 Digital.pdf, network.nmdp.org](https://network.nmdp.org/-/media/project/nmdp/networkresourcecenter/pdfs/services-support/materials-catalog/np24365_donor-selection-guidelines_2025-07-23_digital.pdf?rev=ca5eca0935de408aa028800fbb65e299)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Clinical assessment and procedures › Organ and tissue transplantation › Titles A to La*\n\n*Initially written Sep 29, 2026 · Reviewed: Sep 30, 2026 · Edited: Sep 30, 2026 · Last review: Sep 30, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/hla-typing", "markdown_url": "https://www.edgepedia.org/hla-typing.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"HLA typing\", Edgepedia (EdgeChat), https://www.edgepedia.org/hla-typing. Edgepedia Community License 1.0.", "credit_md": "\"[HLA typing](https://www.edgepedia.org/hla-typing)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/hla-typing](https://www.edgepedia.org/hla-typing). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"HLA typing\", Edgepedia (EdgeChat), https://www.edgepedia.org/hla-typing. Edgepedia Community License 1.0.", "speakable": "HLA typing is the laboratory and computational determination of which human leukocyte antigen alleles a person carries, underpinning transplant donor matching, disease association studies, and drug safety screening." }